AGIO
AgiosFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Positive clinical readouts or a value-accretive partnership that materially de-risks programs and meaningfully extends runway could push shares toward the bull target (~+40% vs anchor).
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +5.8.
What can break
Clinical trial failure or safety signal
Momentum
91
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.08 · Bull $5.19 · Bear $2.60
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $42.38
Why
Momentum91 · Δ7d +5.8
Value41 · Δ7d -0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
91
26% active weight
Current posture
7d trendImproving
Δ7d
+5.8
Δ21d
+14.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 90.7 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$2.36B
Beta
0.91
Shares Out
59.47M
P/E (TTM)
3.8
P/S (TTM)
35.74
P/FCF (TTM) · Derived
-6.01
Rev YoY
+137.7%
EPS YoY
+8.5%
Gross Margin
+82.1%
Op Margin
-1061.8%
Net Debt
-$814.22M
Current Ratio
14.19
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology